Insider Trading Insights: A Closer Look at 4 Low-Cost Stocks

The Dow Jones index slipped over 200 points on Monday. Insider transactions, whether purchases or sales, can offer a glimpse into the faith or apprehension insiders hold regarding a company’s fortunes. For those delving into penny stocks, such movements can play a pivotal role in shaping their investment strategy.

Highlighted below are recent notable insider activities in the arena of penny stocks. For a comprehensive overview, do visit Benzinga’s insider transactions platform.

Insights into Alzamend Neuro

• The Insider Trade: Alzamend Neuro, Inc. ALZN Director Milton C Ault III purchased 2,000 shares at an average cost of $1.06, totaling approximately $2,127.
• Recent Developments: On December 11, 2023, Alzamend Neuro received FDA approval to begin study AL001-PTSD01, a Phase 2A examination of AL001 for post-traumatic stress disorder (PTSD).
• About Alzamend Neuro: Alzamend Neuro Inc is a biopharmaceutical company in its early clinical stages, dedicated to crafting innovative solutions for neurodegenerative diseases and psychiatric disorders, including Alzheimer’s.

Insights into Gain Therapeutics

• The Insider Move: Gain Therapeutics, Inc. GANX Director Jeffrey Scott Riley purchased 30,000 shares at an average price of $3.86, amounting to around $115,770.
• Recent News: Gain Therapeutics appointed Jonas Hannestad, M.D., Ph.D. as its chief medical officer, effective from March 25, 2024.
• About Gain Therapeutics: Gain Therapeutics Inc is a biotechnology entity devising novel small molecule therapies for various health conditions, spanning lysosomal storage disorders, central nervous system ailments, metabolic disorders, and oncology.

For a deeper dive: Investor Sentiment Improves, But Dow Falls Over 200 Points

Insights into Azitra

• The Inside Scoop: Azitra, Inc. AZTR CFO Norm Staskey acquired 47,600 shares at an average price of $0.21, amounting to approximately $10,034.
• Recent Developments: On March 15, Azitra reported a net loss of $1.83 per share for FY23.
• About Azitra: Azitra Inc is an early-stage clinical biopharmaceutical firm centered on formulating therapies for precision dermatology using engineered proteins and live biotherapeutic products for topical application in treating skin diseases.

Insights into Silo Pharma

• The Insider Deal: Silo Pharma, Inc. SILO President and CEO Eric Weisblum purchased 4,508 shares at an average price of $1.93, amounting to around $8,713.
• Recent Progress: On February 28, Silo Pharma completed a successful dose-ranging study of SPC-15 intranasal therapy for PTSD.
• About Silo Pharma: SILO Pharma Inc is a biopharmaceutical venture in its developmental stage, concentrating on novel treatments for overlooked conditions such as stress-induced psychiatric disorders, chronic pain conditions, and diseases of the central nervous system (CNS).

 

Don’t forget to check out our premarket coverage here